Amazon-ULA rocket launch from Cape Canaveral, Florida, may be visible in Fort Myers, Cape Coral
A rocket launch from Florida could potentially blast off on Monday, June 16, and be visible outside of the Sunshine State.
United Launch Alliance will launch the second batch of Amazon satellites into space — and it's possible people can see the Atlas V rocket far outside of Florida.
When ULA launches its massive rocket, depending on cloud cover, Floridians (and visitors) as far as Jacksonville, Cape Coral and Miami could see it light up the sky after liftoff from Cape Canaveral Space Force Station. Visibility from most of Florida is possible, according to ULA.
What's on board ULA Atlas V? Amazon founder Jeff Bezos' Project Kuiper, a global network of satellites, to compete with SpaceX founder-billionaire Elon Musk and Starlink satellites.
This will be the second launch of the Amazon Project Kuiper production satellites, courtesy of the ULA Atlas V rocket. Online, the mission has been called the "Amazon rocket launch" or "the Amazon rocket launch from Florida." Technically, it's an "Amazon-ULA rocket launch" or "Amazon satellite launch." Bezos also founded the private space company Blue Origin, which launches rockets at a facility in Texas and in Cape Canaveral.
➤ Business is booming: Florida's Space Coast is one of fastest-growing economies in U.S.
In Florida, we can best see the "Amazon satellite launch" in person, particularly if you're anywhere on the Space Coast (Melbourne, Florida, area), the Fun Coast (Daytona Beach area) or the Treasure Coast (Vero Beach, Jensen Beach and Fort Pierce).
Below is more information about the rocket launch in Florida and suggestions on where to watch them from here.
Rocket launch tally: Here's a list of all 2025 missions from Cape Canaveral, Florida (psst, there's a lot)
For questions or comments, email FLORIDA TODAY Space Reporter Rick Neale at rneale@floridatoday.com or Space Reporter Brooke Edwards at bedwards@floridatoday.com. For more space news from the USA TODAY Network, visit floridatoday.com/space.
Tom Cruise and untitled SpaceX project: 'Mission: Impossible' star who lives in Florida may shoot a film in outer space
Mission: United Launch Alliance will launch an Atlas V rocket carrying Amazon's second batch of broadband satellites for its Project Kuiper constellation. Amazon's Project Kuiper is Jeff Bezos' attempt to compete with SpaceX founder Elon Musk's Starlink satellite mission.
Launch window: 1:25 p.m. ET Monday, June 16, 2025
Launch location: Launch complex 41 at Cape Canaveral Space Force Station in Cape Canaveral, Florida
Sonic booms: No
Trajectory: Northeast − it's possible the ULA Atlas V rocket will be visible outside of Florida after liftoff, from Cape Canaveral to New Jersey.
Live coverage starts two hours minutes before liftoff at : You can watch live rocket launch coverage from USA TODAY Network's Space Team, which consists of FLORIDA TODAY space reporters Rick Neale and Brooke Edwards and visuals journalists Craig Bailey, Malcolm Denemark and Tim Shortt. Our Space Team will provide up-to-the-minute updates in a mobile-friendly live blog, complete with a countdown clock, at floridatoday.com/space, starting 90 minutes before liftoff. You can download the free FLORIDA TODAY app, which is available in the App Store or Google Play, or type into your browser.
Shown is the National Weather Service-Melbourne radar, which shows conditions in real-time for the Space Coast, Brevard County, Orlando and other parts of Florida. The current date and time show up on the bottom right of this radar embed; otherwise, you may need to clear your cache.
ULA provided a helpful graphic (see above) that shows the Atlas V launch of Kuiper 2 for Amazon and its intended flight path and launch visibility.
Note: Cities in the Space Coast of Florida, which is in Brevard County and measures 72 miles of coast, include Titusville, Mims, Port St. John, Merritt Island, Cocoa, Cocoa Beach, Melbourne, West Melbourne, Palm Bay, Satellite Beach, Indian Harbour Beach, Indialantic, Melbourne Beach, Grant-Valkaria and Sebastian.
Launch, Space Coast, east Orlando, near University of Central Florida, Bithlo, the northern part of the Treasure Coast, Indian River County, Sebastian, Vero Beach, parts of Daytona Beach, New Smyrna Beach and Oak Hill
1: Launch + 30 seconds, Space Coast, Orlando, the Treasure Coast, Indian River County, Sebastian, Vero Beach, Daytona Beach, New Smyrna Beach and Oak Hill, Volusia County, St. Augustine, Ocala, Lakeland area
2: Launch + 90 seconds, which includes PLF Jettison or separation and jettison of the payload fairing: Space Coast, Daytona Beach, New Smyrna Beach, Oak Hill, Port Orange, Volusia County, Treasure Coast, Indian River County, Martin County, St. Lucie County, Orlando, Sanford, Kissimmee, Central Florida, Ocala, Lakeland, St. Augustine, Ponte Vedra Beach
3: Launch + 150 seconds, which includes solid rocket booster jettison, visibility extends to Sebring, Winter Haven, Palatka, Gainesville, Jacksonville, Sarasota, Manatee County, Sarasota County, Tampa, St. Petersburg, Cape Coral, Fort Myers, Naples, Collier County, Lee County, Clearwater, West Palm Beach, Lake Worth Beach, Wellington, Jupiter, Mar-a-Lago, Palm Beach, southern Georgia, Savannah, Georgia, parts of the Caribbean, the Bahamas
4: Launch + 210 seconds, which includes booster separation, Tallahassee, Panama City, Panhandle, Big Bend area of Florida; visibility extends beyond Florida to Georgia, South Carolina, parts of North Carolina
5: Launch + 270 seconds, ULA Atlas V rocket launch visibility extends beyond Florida to these other states and cities:
Georgia; Savannah, Georgia; Atlanta, Georgia; Columbus, Georgia
Alabama; Dothan, Alabama; just outside Birmingham, Alabama
Tennessee; Knoxville, Tennessee; just outside Huntsville, Tennessee; just outside Nashville, Tennessee
Kentucky
South Carolina; Spartanburg, South Carolina
North Carolina; High Point, North Carolina; Winston-Salem, North Carolina; Charlotte, North Carolina; Wilmington, North Carolina
Virginia; Virginia Beach, Virginia; Richmond, Virginia
West Virginia; Charleston, West Virginia
Maryland; Washington, Maryland
Delaware; Annapolis, Delaware; Dover, Delaware
6: Launch + 330 seconds, ULA Atlas V rocket launch visibility extends beyond Florida to these other states and cities:
New Jersey: Trenton, New Jersey; New York, New Jersey
Pennsylvania: Philadelphia, Pennsylvania; Harrisburg, Pennsylvania; Pittsburgh, Pennsylvania; Erie, Pennsylvania
Ohio: Cleveland, Ohio; Columbus, Ohio; Cincinnati, Ohio; Toledo, Ohio
Indiana: just outside Indianapolis, Indiana; Fort Wayne, Indiana
Michigan: Detroit, Michigan
Kentucky: just outside Louisville, Kentucky
Rhode Island: Providence, Rhode Island
Connecticut: Hartford, Connecticut
Massachusetts: Boston, Massachusetts
New York: Binghamton, New York; Albany, New York
7: Launch + 390 seconds, visibility of Atlas V rocket may be possible in these states:
Alabama
Tennessee
Kentucky
Georgia
South Carolina
North Carolina
Virginia
West Virginia
Ohio
Indiana
Michigan
Delaware
Maryland
New Jersey
Pennsylvania
New York
Rhode Island
Connecticut
Massachusetts
New Hampshire
Vermont
Maine
Toronto, Canada
The above guidelines are estimates based on the graphic provided by ULA.
Sangalang is a lead digital producer for USA TODAY Network. Follow her on Twitter or Instagram at @byjensangalang. Support local journalism. Consider subscribing to a Florida newspaper.
This article originally appeared on Fort Myers News-Press: Florida rocket launch: Will Atlas V be seen in Fort Myers after liftoff
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / ACCESS Newswire / June 15, 2025 / Adolore BioTherapeutics ('Adolore' or the 'Company'), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, 'Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1,' in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, 'Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102.' The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project,' 'will,' 'should,' 'may,' 'plan,' 'intend,' 'assume' and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542 [email protected] SOURCE: Adolore Biotherapeutics, Inc. press release
Digital Trends
2 hours ago
- Digital Trends
SpaceX's Starlink rival is about to launch more internet satellites — here's how to watch
Amazon is preparing to launch its second batch of Project Kuiper internet satellites to orbit as it seeks to build out a constellation to take on SpaceX's Starlink service. The KA-02 mission had been delayed due to inclement weather, but Amazon and rocket provider United Launch Alliance (ULA) appear confident that it can send the satellites skyward on Monday, June 16. An Atlas V 551 rocket, configured with five side-mounted solid rocket boosters and a medium-length payload fairing, will launch the Project Kuiper satellites from Cape Canaveral in Florida. Amazon launched its first batch of 27 Project Kuiper satellites a couple of months ago, and Monday's mission will also carry the same number. The company is hoping to launch a global high-speed, low-latency satellite-powered internet service with as few as 1,000 satellites by the end of this year. Building out the constellation to the targeted 3,200 satellites will help to boost network performance and reliability for paying customers. SpaceX's Starlink initiative began deploying internet satellites in 2019 and so has a major head start on Amazon, but over time, Project Kuiper hopes to differentiate itself by offering affordable user terminals as well as exploiting Amazon Web Services for advanced cloud integration. By focusing on seamless connectivity for remote and underserved regions, and integrating with existing telecom infrastructure, Project Kuiper is seeking to carve out a significant share in the rapidly growing internet satellite sector, though clearly it's going to take several years to before it has any chance of reaching its goal. How to watch Amazon and ULA are targeting 1:25 p.m. ET (10:25 a.m. PT) on Monday, June 16, for the launch the KA-02 mission from Cape Canaveral in Florida. You can watch a livestream of the launch via the player embedded at the top of this page. The broadcast will begin at about 1 p.m. ET (10 a.m. PT). Additionally, if you live on the East Coast and the skies are clear, there's a chance you'll be able to see the rocket heading to orbit. This chart reveals how many seconds after launch it will take for the rocket to become visible, depending on your location.
Yahoo
6 hours ago
- Yahoo
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
